unknown
Stage
About
Deck Therapeutics is a biopharmaceutical company developing THDG3, a semi-synthetic intravenous omega-3 fatty acid glyceride emulsion designed as a neuroprotectant for hypoxic‑ischemic brain injuries such as neonatal hypoxic‑ischemic encephalopathy and ischemic stroke; the compound was developed at Columbia University.
Explore Deck Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.